Decades after the United States outlawed cannabis and carried out a drug war that had devastating effects on Black and Brown communities, the controversial plant is gaining popularity as an alternative medicine. Although prohibition has significantly hindered cannabis research, studies show that cannabis can be effective against some medical conditions including chronic pain and post-traumatic stress disorder (PTSD).
An early-stage biotech startup called Cannaformatics has recently published research in the “Cannabis and Cannabinoid Research” journal, showing how cannabis can interact with pathways in the brain to reduce autism in kids. Titled “The Potential of Salivary Lipid-Based Cannabis-Responsive Biomarkers to Evaluate Medical Cannabis Treatment in Children with ASD,” the research paper outlines possible pathways for treating juvenile autism.
Specifically, the paper points out 22 new lipid-based biomarkers that can be used to facilitate cannabis treatment in kids with autism spectrum disorder. This includes lipids in the central nervous system that would theoretically allow cannabis to have an effect on the neuron function of children diagnosed with ASD.
Cannaformatics is hoping the discovery of these biomarkers will bring it one step closer to developing personalized services to patients and healthcare providers who would like to use cannabinoid-derived treatments. The company first published a paper from its Autism Spectrum Disorder (ASD) pilot in December 2021. The pilot ASD study is sponsored by Whole Plant Access for Autism and Canniatric.
The first paper provided evidence of cannabis-responsive biomarkers and established them as a standard tool for determining the effect of medical marijuana. In conjunction, the two research papers illustrate how cannabis-responsive biomarkers could potentially be used to create marijuana treatments for patients and develop next-gen applications and medicines based on cannabinoids.
Cannaformatics CEO and cofounder Itzhak Kurek says that unmasking marijuana’s working mechanisms has allowed the company to show that cannabis-responsive biomarkers can grant clinicians and life-science companies new tools to help them understand how cannabis can help maintain central nervous system homeostasis in kids with ASD.
Research published in the latest paper also opens up new avenues for studying cannabis’ ability to alleviate neurodegenerative diseases such as Parkinson’s disease, ALS and Alzheimer’s disease. Cannaformatics is ready to put together the capital it needs to launch its ASD service platform and begin research on cannabis’ impact on neurodegenerative diseases.
According to chief commercial officer Kenneth Epstein, publishing the second paper was an important moment for Cannaformatics as it proves that the company’s technology is valid and places them at the forefront of biotechnology in the medical marijuana treatment segment.
As more research comes out about the potential therapeutic applications of cannabis, the public will keep evolving in its perception of the various marijuana products sold companies such as Flora Growth Corp. (NASDAQ: FLGC) in the different markets in which they operate.
NOTE TO INVESTORS: The latest news and updates relating to Flora Growth Corp. (NASDAQ: FLGC) are available in the company’s newsroom at https://cnw.fm/FLGC
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CNW420.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW420? Ask our Editor
CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CNW420 is part of the InvestorBrandNetwork.
